The frequent exacerbator: A new phenotype in chronic obstructive pulmonary disease?

Hot Topics in Respiratory Medicine

Volumn , Issue 19, 2011, Pages 7-12

  Soler Cataluña, Juan J ^a   Martínez García, Miguel Á ^a   Serra, Pablo Catalán ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CCL1 CHEMOKINE; CORTICOSTEROID; MACROLIDE; MANNOSE BINDING LECTIN 2; MOXIFLOXACIN; ROFLUMILAST; TOBRAMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; AUTOIMMUNITY; BRONCHIECTASIS; BRONCHITIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; EOSINOPHIL; FORCED EXPIRATORY VOLUME; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84863471021     PISSN: 19739664     EISSN: 20360886     Source Type: Book Series    
DOI: 10.4147/HTR-111907     Document Type: Article

References (51)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555.
2. Agusti A, Calverley P, Celli B, et al; on behalf of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11(1):122.
3. Han MK, Agustí A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am J Respir Crit Care Med 2010;182:598-604.
4. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL; on behalf of the EOLO group. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 2000;67:495-501.
5. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.
6. Soler-Cataluña JJ, Rodríguez-Roisin R. Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious? COPD 2010;7:276-284.
7. Tashkin DP. Frequent exacerbations of chronic obstructive pulmonary disease-a distinct phenotype? N Engl J Med 2010;363(12): 1183-1184.
8. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
9. Soler JJ, Sánchez L, Román P, Martínez MA, Perpiña M. Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Respir Med 2004;98:318-329.
10. Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007;30:907-913.
11. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:698-702.
12. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004;59:387-395.
13. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008;177:396-401.
14. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA. Relationship between depression and exacerbations in COPD. Eur Respir J 2008;32:53-60.
15. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997;10:417-423.
16. Donaldson GC, Hurst JR, Smith CJ, Hubbar RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of chronic obstructive pulmonary disease. Chest 2010; 137:1091-1097.
17. Terada K, Muro S, Sato S, et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax 2008;63:951-955.
18. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
19. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007;131:696-704.
20. Soler-Cataluña JJ, Martínez-García MA, Román-Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-931.
21. Soler-Cataluña JJ, Martínez-García MA, Sánchez L, Perpiña M, Román P. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009;103:692-699.
22. Soler JJ, Sánchez L, Latorre M, Alamar J, Román P, Perpiña M. The impact of COPD on hospital resources: the specific burden of COPD patients with high rates of hospitalization. Arch Bronconeumol 2001;37:375-381.
23. Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, Niederman MS. Acute exacerbation of COPD: factors associated with poor outcome. Chest 2000;117:662-671.
24. Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007;131:20-28.
25. Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009;135:975-982.
26. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-120.
27. Patel IS, Seemungal TA, Wiks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57:759-764.
28. Tumkaya M, Atis S, Ozge C, Delialioglu N, Polat G, Kanik A. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med 2007;101:729-737.
29. Zhang M, Li Q, Zhang Y-Y, Ding X, Zhu D, Zhou X. Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease. Eur J Clin Microbiol Infect Dis 2010;29:1487-1493.
30. Wan ES, DeMeo DL, Hersh CP, et al. Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). Respir Med 2011;105:588-594.
31. Foreman MG, DeMeo DL, Hersh CP, Reilly JJ, Silverman EK. Clinical determinants of exacerbations in severe, early-onset COPD. Eur Respir J 2007;30:1124-1130.
32. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995;8:1333-1338.
33. Martínez-García MA, Soler-Cataluña JJ, Donat Y, et al. Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients. Chest 2011 May 5 [Epub ahead of print].
34. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of COPD: identification of biological clusters and their biomarkers. Am J Respir Crit Care Med 2011 Jun 16 [Epub ahead of print].
35. Soler N, Agustí C, Angrill J, Puig de la Bellacasa J, Torres A. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007;62:29-35.
36. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J 2002;20(Supl 36):9s-19s.
37. Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:356-361.
38. Terada K, Muro S, Ohara T, et al. Abnormal swallowing reflex and COPD exacerbation. Chest 2010;137:326-333.
39. Abroug F, Quanes-Besbes L, Nciri N, et al. Association of leftheart dysfunction with severe exacerbation of chronic obstructive pulmonary disease. Diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006;174:990-996.
40. Harvey MG, Hancox RJ. Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emerg Med Australas 2004;16:212-215.
41. Zvezdin B, Milutinov S, Kojicic M, et al. A postmorten analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009;136:329-330.
42. Takabatake N, Shibata Y, Abe S, et al. A Single nucleotide polymorphism in the CCL1 gene predicts acute exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:875-885.
43. Yang IA, Seeney SL, Wolter JM, et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun 2003;4:269-274.
44. Eisen DP. Mannose-binding lectin deficiency and respiratory tract infection. J Innate Immun 2010;2:114-122.
45. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.
46. Szafransky W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol and formoterol in chronic obstructive pulmonary diseases. Eur Respir J 2003;22:912-918.
47. Calverley PM, Sánchez Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-161.
48. Fabbri LM, Calverley PM, Izquierdo Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703.
49. Seemungal TA, Wilkinson TM, Hurst JR. Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-1147.
50. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010;11:10.
51. Dal Negro R, Micheletto C, Tognella S, Visconti M, Turati C. Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv Ther 2008;25:1019-1030.